[January 16, 2013]

Research and Markets: IMA901 (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 for US, EU5 and Japan

Research and Markets (http://www.researchandmarkets.com/research/vttl7x/ima901_renal) has announced the addition of GlobalData's new report "IMA901 (Renal Cell Carcinoma) - Analysis and Forecasts to 2022" to their offering.

IMA901 (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 provides IMA901 sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (205-2022). The report also includes information on Renal Cell Carcinoma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2015-2022 for all seven major markets

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 RCC Disease: Market Characterization

4 IMA901

5 Appendix

For more information visit http://www.researchandmarkets.com/research/vttl7x/ima901_renal

Source (News - Alert): GlobalData

[ Back To Technology News's Homepage ]